Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ethyl-EPA (Miraxion™)
Ethyl-EPA · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Ethyl-EPA (Miraxion™) | DRUG | - |
Inclusion Criteria: * Clinical features of Huntington's disease (HD) and confirmatory family history of HD, and/or CAG repeat expansion greater than or equal to 36 * Ambulatory, not requiring skilled nursing care (total functional capacity \[TFC\] greater than or equal to 7) * Chorea score of at le...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE3 | Valbenazine |
| Hoffmann-La Roche | RHHBY | 3 | PHASE2 | Tominersen, RG6496, SPK-10001 |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | AMT-130 |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |
Ethyl-EPA is an investigational small molecule being studied for the treatment of mild to moderate Huntington Disease, a progressive neurological disorder. It has been evaluated in a Phase 3 clinical trial called TREND-HD. Ethyl-EPA is not approved for any indication and remains in clinical development.
Ethyl-EPA is being developed by Amarin Corporation plc, a biopharmaceutical company whose ticker symbol is AMRN. Amarin sponsored the Phase 3 TREND-HD trial of Ethyl-EPA in Huntington Disease.
Ethyl-EPA is in Phase 3 development for Huntington Disease. The only listed trial, TREND-HD, is a completed Phase 3 study. Ethyl-EPA is investigational and has not been approved by the FDA for any use.
Ethyl-EPA has been studied in one clinical trial: NCT00146211, also known as TREND-HD. This completed Phase 3 trial enrolled 300 participants with mild to moderate Huntington Disease across the United States and Canada. It was randomized and double-blind, with participants aged 35 years and older.
Yes, Ethyl-EPA is also known as Miraxion. Miraxion is a brand name used for Ethyl-EPA, the investigational small molecule developed by Amarin Corporation plc for Huntington Disease. Both names refer to the same drug candidate.